Apogee Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
APGE Nasdaq 8731 https://apogeetherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Apogee Therapeutics Inc

With 54% institutional ownership, Apogee Therapeutics, Inc. (NASDAQ:APGE) is a favorite amongst the big guns - Apr 16th, 2024 12:48 pm
Paragon’s hub-and-spoke biotech model yields another reverse merger - Apr 3rd, 2024 11:49 am
Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why - Mar 28th, 2024 3:01 pm
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases - Mar 25th, 2024 11:00 am
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million - Mar 12th, 2024 8:01 pm
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering - Mar 7th, 2024 11:49 pm
Insiders Of Apogee Therapeutics Reap Rewards After Their Investment Jumps Another US$74m - Mar 6th, 2024 11:02 am
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering - Mar 5th, 2024 9:23 pm
Apogee Catapults 42% After Eczema Drug Blows Expectations Out Of The Water - Mar 5th, 2024 9:16 pm
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results - Mar 5th, 2024 11:10 am
Apogee data hint at potential for long-lasting eczema drug - Mar 5th, 2024 11:00 am
Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days - Mar 5th, 2024 11:00 am
Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024 - Mar 4th, 2024 9:01 pm
Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference - Jan 2nd, 2024 12:30 pm
We Think Apogee Therapeutics (NASDAQ:APGE) Can Easily Afford To Drive Business Growth - Nov 21st, 2023 6:19 pm
Apogee Therapeutics Inc Reports Q3 2023 Financial Results and Corporate Progress - Nov 15th, 2023 9:44 am
Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results - Nov 13th, 2023 12:30 pm
Apogee Therapeutics to Participate in Upcoming November Investor Conferences - Oct 30th, 2023 12:00 pm
7 Biotech Stocks to Get In Now Before Investors Catch On - Oct 23rd, 2023 6:50 am
Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress - Sep 27th, 2023 12:42 pm